NEWS RELEASE

Omeros to Present at the 15th Annual Needham Healthcare Conference

2016-04-07

SEATTLE--(BUSINESS WIRE)--Apr. 7, 2016-- Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 15th Annual Needham Healthcare Conference in New York next week. The presentation is scheduled for Wednesday, April 13, 2016, at 2:20 p.m. EDT.

The presentation will be webcast. The live and archived webcasts can be accessed on the “Events” page of the company’s website at **www.omeros.com**.

About Omeros Corporation

Omeros is a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery® platform, the company’s first drug product, OMIDRIA® (phenylephrine and ketorolac injection) 1%/0.3%, was broadly launched in the U.S. in April 2015 for use during cataract surgery or intraocular lens (IOL) replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce

postoperative ocular pain. In the European Union, the European Commission has approved OMIDRIA for use in cataract surgery and lens replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain. Omeros has five clinical-stage development programs focused on: complement-related thrombotic microangiopathies; complement-mediated glomerulopathies; Huntington's disease and cognitive impairment; addictive and compulsive disorders; and preventing problems associated with urologic surgical procedures. In addition, Omeros has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development, and a platform used to generate antibodies.

View source version on businesswire.com: **http://www.businesswire.com/news/home/20160407005402/en/**

Source: Omeros Corporation

Investor and Media Relations:
Cook Williams Communications, Inc.
Jennifer Cook Williams, 360-668-3701
jennifer@cwcomm.org